Raymond James Financial Inc. bought a new position in shares of CorVel Co. (NASDAQ:CRVL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 225,805 shares of the business services provider's stock, valued at approximately $25,123,000. Raymond James Financial Inc. owned about 0.44% of CorVel as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of CRVL. Atria Investments Inc grew its stake in CorVel by 8.6% during the 3rd quarter. Atria Investments Inc now owns 4,234 shares of the business services provider's stock valued at $1,384,000 after purchasing an additional 335 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in shares of CorVel during the third quarter valued at $298,000. Quest Partners LLC grew its position in CorVel by 95.1% in the 3rd quarter. Quest Partners LLC now owns 3,596 shares of the business services provider's stock worth $1,175,000 after purchasing an additional 1,753 shares during the last quarter. Premier Fund Managers Ltd acquired a new stake in CorVel in the 3rd quarter valued at approximately $918,000. Finally, Advisors Asset Management Inc. raised its stake in shares of CorVel by 121.7% during the third quarter. Advisors Asset Management Inc. now owns 204 shares of the business services provider's stock valued at $67,000 after purchasing an additional 112 shares in the last quarter. Institutional investors and hedge funds own 51.36% of the company's stock.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded shares of CorVel from a "buy" rating to a "hold" rating in a report on Thursday, March 13th.
Get Our Latest Report on CorVel
Insiders Place Their Bets
In other CorVel news, Director Steven J. Hamerslag sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $123.48, for a total transaction of $1,234,800.00. Following the transaction, the director now owns 314,000 shares of the company's stock, valued at $38,772,720. The trade was a 3.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Brandon O'brien sold 1,523 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $119.56, for a total transaction of $182,089.88. Following the completion of the sale, the chief financial officer now directly owns 17,142 shares in the company, valued at approximately $2,049,497.52. The trade was a 8.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,200 shares of company stock valued at $3,824,115 in the last 90 days. 47.57% of the stock is currently owned by insiders.
CorVel Trading Up 2.5 %
NASDAQ CRVL traded up $2.69 on Wednesday, reaching $108.48. The stock had a trading volume of 64,688 shares, compared to its average volume of 105,633. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of 63.81 and a beta of 1.06. The business has a 50 day moving average price of $112.09 and a 200 day moving average price of $114.20. CorVel Co. has a 1 year low of $76.20 and a 1 year high of $128.61.
CorVel (NASDAQ:CRVL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The business services provider reported $0.46 earnings per share (EPS) for the quarter. CorVel had a net margin of 10.12% and a return on equity of 32.22%.
About CorVel
(
Free Report)
CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.
Further Reading
Before you consider CorVel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorVel wasn't on the list.
While CorVel currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
